TAM April/May 2022 CME Posttest

To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.

Learning Objectives

On completion of this activity, the learner will be able to:

• Describe the important new data presented at the 2022 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of epidemiologic trends, prevention research, and basic science research in the HIV and SARS-CoV-2 pandemics
• Describe the potential treatment options for depression and bipolar depression disorders and understand how it impacts those with HIV
• Describe the current epidemiology of tuberculosis, shorter regimens for its treatment, and recent advancements in treatment for patients with drug-resistant tuberculosis

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.

Intended Audience

This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections.

This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from May 17, 2022 to May 17, 2023. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.

Disclosure of Financial Interests

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.

All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with ineligible companies (formerly known as “commercial interests”) within the past 24 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines an ineligible company as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.” The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with ineligible companies, enabling the audience members to form their own judgments about such associations.

The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for contributors and planners/reviewers is below. Information about financial relationships with ineligible companies for contributors is also included in each article.

Contributors
Dr Stevenson has no relevant financial affiliations with ineligible companiesto disclose. (Updated on May 2, 2022)

Dr Buchbinder has no relevant financial affiliations with ineligible companies to disclose. (Updated on May 16, 2022)

Dr Liu has received research funding from Gilead Sciences and Viiv Healthcare and has participated in research trials that received provision of medicines from Gilead Sciences, Inc. (Updated on May 16, 2022)

Dr Fuenmayor has no relevant financial affiliations with ineligible companies to disclose. (Updated on May 10, 2022)

Dr Cournos has no relevant financial affiliations with ineligible companies to disclose. (Updated on May 10, 2022)

Dr Ignatius has no relevant financial affiliations with ineligible companies to disclose. (Updated on May 16, 2022)

Dr Swindells has received research grants paid to her institution from ViiV Healthcare. (Updated on May 16, 2022)

Planner/reviewer 1 has been a consultant to Antiva Biosciences, Gilead Sciences, Inc., and Merck and Co, Inc. (Updated on April 20, 2022)

Planner/reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated on May 11, 2022)

Reviewer 3 has no relevant financial relationships with ineligible companies to disclose. (Updated on April 27, 2022)

Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc., and Merck & Co, Inc. (Updated on April 20, 2022)

Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, has received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. (Updated on January 28, 2022)

Dr Hirsch has no relevant financial relationships with ineligible companies to disclose. (Updated on April 27, 2022)

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

Independent educational grants for the 2022 Improving the Management of HIV Disease® CME program:

PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare

SILVER SUPPORTER
Janssen Therapeutics

BRONZE SUPPORTER
Theratechonologies Inc

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.

Contact Information

If you have any questions about this activity, please contact the IAS–USA:

Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400

By clicking the link below, I acknowledge that I have read these instructions and understand them.